Abstract:In recent study, in order to improve the bioavailability of endomorphin-1 (EM-1), we designed and synthesized a series of novel EM-1 analogs by replacement of L-Pro2 by β-Pro, D-Ala or Sar, together with C-terminal oligoarginine-conjugation. Our results indicated that the introduction of D-Ala and β-Pro in position 2, along with oligoarginine-conjugation, didn't significantly decrease the μ-affinity and in vitro bioactivity, and the enhancement of arginine residues did not markedly influence the μ-affinity of these analogs. All analogs displayed a significant enhancement of stability, which may be due to increased resistance to proline-specific enzymatic degradation. Moreover, following intracerebroventricular (i.c.v.) administration, analogs 1, 2, 4 and 5 produced significant antinociception and increased duration of action, with the ED50 values being about 1.8- to 4.2-fold less potent than that of EM-1. In addition, our results indicated that no significant antinociceptive activity of EM-1 was seen following subcutaneous (s.c.) injection, whereas analogs 1, 2, 4 and 5 with equimolar dose induced significant and prolonged antinociception by an opioid and central mechanism. Herein, we further examined the gastrointestinal transit and colonic propulsive latencies of EM-1 and its four analogs administered centrally and peripherally. I.c.v. administration of EM-1 and analogs 1, 2, 4 and 5 significantly delayed gastrointestinal transit and colonic bead propulsion in mice, but the inhibitory effects induced by these analogs were largely attenuated. It is noteworthy that no significant gastrointestinal side effects induced by these four analogs were observed after s.c. administration. Our results demonstrated that combined modifications of EM-1 with unnatural amino acid substitutions and oligoarginine-conjugation gave an efficient strategy to improve the analgesic profile of EM-1 analogs but with less gastrointestinal side effects when administered peripherally.

In vitro and in vivo characterization of opioid activities of endomorphins analogs with novel constrained C-terminus: evidence for the important role of proper spatial disposition of the third aromatic ring.

In Vitro and in Vivo Characterization of Opioid Activities of C-terminal Esterified Endomorphin-2 Analogs

Structure-activity study on the spatial arrangement of the third aromatic ring of endomorphins 1 and 2 using an atypical constrained C terminus.

Structure–activity Study of Endomorphin-2 Analogs with C-terminal Modifications by NMR Spectroscopy and Molecular Modeling

Structure-Activity Study of Endomorphins Analogs with C-Terminal Substitution

Characterization of Opioid Activities of Endomorphin Analogs with C-Terminal Amide to Hydrazide Conversion

Structure-activity Relationship of Endomorphins and Their Analogs

Novel endomorphin-1 analogs with C-terminal oligoarginine-conjugation display systemic antinociceptive activity with less gastrointestinal side effects.

Design, Synthesis, and Biological Activity of New Endomorphin Analogs with Multi-Site Modifications

Design, Synthesis, and Evaluation of New Endomorphin Analogs with Enhanced Central Antinociception after Peripheral Administration.

Structure–activity Relationships of Novel Endomorphin-2 Analogues with N–O Turns Induced by Α-Aminoxy Acids

Synthesis and Antinociceptive Effects of Endomorphin-1 Analogs with C-terminal Linked by Oligoarginine

Endomorphin-2 Analogs with C-terminal Esterification Produce Potent Systemic Antinociception with Reduced Tolerance and Gastrointestinal Side Effects

Design, Synthesis, and Pharmacological Characterization of Novel Endomorphin-1 Analogues As Extremely Potent Μ-Opioid Agonists.

Synthesis and Biological Evaluations of Novel Endomorphin Analogues Containing Α-Hydroxy-β-phenylalanine (AHPBA) Displaying Mixed Μ/δ Opioid Receptor Agonist and Δ Opioid Receptor Antagonist Activities.

Endomorphin-1 Analogs with Oligoarginine-Conjugation at C-terminus Produce Potent Antinociception with Reduced Opioid Tolerance in Paw Withdrawal Test.

Endomorphin 1[psi] and Endomorphin 2[psi], Endomorphins Analogues Containing A Reduced (ch2nh) Amide Bond Between Tyr(1) and Pro(2), Display Partial Agonist Potency but Significant Antinociception

A New Class of Highly Potent and Selective Endomorphin-1 Analogues Containing Α-Methylene-β-aminopropanoic Acids (Map).

Endomorphins: Promising Endogenous Opioid Peptides for the Development of Novel Analgesics

Opioid Receptor Binding and Antinociceptive Activity of the Analogues of Endomorphin-2 and Morphiceptin with Phenylalanine Mimics in the Position 3 or 4.

Novel Cyclic Endomorphin Analogues with Multiple Modifications and Oligoarginine Vector Exhibit Potent Antinociception with Reduced Opioid-like Side Effects